|
Gabapentin in Fibromyalgia Trial (GIFT) Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on Gabapentin in Fibromyalgia Trial (GIFT) conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Gabapentin in Fibromyalgia Trial (GIFT) Clinical research trials and Gabapentin in Fibromyalgia Trial (GIFT) health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like Gabapentin in Fibromyalgia Trial (GIFT). Gabapentin in Fibromyalgia Trial (GIFT) Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Gabapentin in Fibromyalgia Trial (GIFT) clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their Gabapentin in Fibromyalgia Trial (GIFT) condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "G" Clinical Trials Conditions > Gabapentin in Fibromyalgia Trial (GIFT)  Gabapentin in Fibromyalgia Trial (GIFT)
Gabapentin in Fibromyalgia Trial (GIFT)
For Condition: Fibromyalgia
Status: Recruiting
Sponsor(s): National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) ,
Synopsis: This study will assess the safety and effectiveness of the drug gabapentin in reducing pain associated with primary fibromyalgia.
Details: Fibromyalgia, a chronic musculoskeletal pain disorder of unknown etiology, is characterized by widespread musculoskeletal pain, fatigue, and multiple tender points; the disease affects 3 to 6 million Americans. A person is considered to have fibromyalgia if he or she has widespread pain in combination with tenderness in at least 11 of 18 specific tender point sites. Treatment of fibromyalgia requires a comprehensive approach and includes aerobic exercise, heat and massage, antidepressant medications, and relaxation. Gabapentin, a medication used to treat seizures, has been shown to work on pain transmission pathways and may relieve the pain associated with fibromyalgia. This study will assess the efficacy of gabapentin in reducing pain severity in fibromyalgia as measured by the average pain item of the Brief Pain Inventory (BPI) score. Patients will be randomized to receive gabapentin or placebo. The gabapentin dose will be titrated for persisting symptoms and as tolerated during the first 6 weeks of the study, reaching final doses between 1800 mg/day and 2400 mg/day. Patients will then continue on the final dose for the remaining 6 weeks of the study. Following completion of the 12 week treatment phase, patients will be tapered off of the medication over 1 week. The effectiveness of gabapentin will be assessed using the BPI. The BPI is a self-administered questionnaire that measures the severity of pain and the interference of pain on function over the past 24 hours. Other assessments will include the total Fibromyalgia Impact Questionnaire (FIQ) score; six 11-point Likert-type scales in the FIQ that measure pain, fatigue, morning tiredness, stiffness, anxiety, and depression; the mean tender point pain threshold; Clinical Global Impression of Severity (CGI-Severity); Patient Global Impression of Improvement (PGI-Improvement); the Short-form McGill Pain Questionnaire (SF-MPQ); the Medical Outcomes Study Short Form-36 (SF-36); the Montgomery Asberg Depression Rating Scale (MADRS); and the Medical Outcomes Sleep Scale (MOS-Sleep).
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Primary fibromyalgia as defined by the American College of Rheumatology (ACR) - Score > 4 on the average pain item of the BPI at screening - Ability to understand and cooperate with study procedures - Acceptable methods of contraception Exclusion Criteria: - Unwillingness or inability to provide written informed consent. - Lifetime history of psychosis, hypomania or mania, epilepsy, or dementia - History of seizures or status epilepticus - DSM-IV diagnosis of alcohol or substance dependence with the exception of nicotine dependence within 6 months prior to screening visit - A positive urine drug screen for any substances of abuse or excluded medication. (NOTE: If the participant has a positive drug screen at Visit 1 for an excluded medication that may not have had an adequate wash-out period, a retest may be performed prior to Visit 2. If the retest is positive, the participant will be excluded.) - Serious suicide risk - Treatment refractory in the opinion of study official - Pregnant or breastfeeding - Clinically unstable medical or psychiatric condition that could interfere with the absorption, metabolism, excretion, or safety of gabapentin or interfere with the assessment of disease severity - Thyroid-stimulating hormone (TSH) concentrations outside the range of 0.30-8.0 UlU/mL. (NOTE: Participants who have been on a stable dose of thyroid supplementation for at least the past 3 months, have medically appropriate TSH values, and are clinically euthyroid may participate in the study.) - Any screening laboratory assay that is outside of the local laboratories’ normal range by more than 20% or is deemed to be a clinically significant abnormality by the investigator, with the exception of liver function tests (AST, ALT, alkaline phosphatase) which must be within 1.5 X upper limit of normal - Inability to exclude traumatic injury, regional or structural rheumatic disease, or infectious arthropathy as the etiology of their relevant symptoms and that would interfere with interpretation of outcome measures (e.g., osteoarthritis, bursitis, tendonitis) - History of an autoimmune disease or inflammatory arthritis, such as systemic lupus erythematosis (SLE) or rheumatoid arthritis (RA). - An abnormal Westergren erythrocyte sedimentation rate (e.g., ESR > 40 mm/min) - An abnormal antinuclear antibody (ANA > 1:160) or rheumatoid factor (RF >15 IU/ml) - Treatment with a monoamine oxidase inhibitor, tricyclic, SSRI antidepressant (with the exception of fluoxetine), or lithium within 2 weeks prior to beginning study medication - Treatment with fluoxetine within 30 days prior to beginning study medication - Treatment with analgesic medication (with the exception of acetaminophen and over-the-counter NSAIDs) within 1 week prior to beginning study medication - Treatment with any other excluded medications that cannot be discontinued at the screening visit (see Table 2 for a list of excluded medications) - Previous treatment with gabapentin - Previous treatment with pregabalin - Treatment with any other investigational medications within 30 days prior to screening
Total Enrollment: 150
Location and Contact Information:
Overall Study Official:
LesleyArnold, Principal Investigator, University of Cincinnati
McLean Hospital/Harvard Medical School (must live in the Boston, MA area) *Recruiting*
Belmont, Massachusetts, 02478
United States
Recruiting Judith Berry 617-855-2434
University of Cincinnati College of Medicine, Department of Psychiatry (must live in the Cincinnati, OH area) *Recruiting*
Cincinnati, Ohio, 45267
United States
Recruiting Carrie Gibson 513-558-0508
Newton-Wellesley Hospital (must live in the Boston, MA area) *Recruiting*
Newton, Massachusetts, 02462
United States
Recruiting Mary Rogers 617-243-5440
Additional Information:
Study ID Numbers: NIAMS-089; 1N01 AR22264
Study Start Date: March 2003
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00057278
Other Fibromyalgia Studies:
1. Intravenous micronutrient therapy (IVMT) for Fibromyalgia
2. Glucocorticoid Effects on Cellular Cytokine Release
3. Genetics of Fibromyalgia
4. The Efficacy of Reiki in the Treatment of Fibromyalgia
5. Fibromyalgia: A Randomized Controlled Trial of a Mind/Body Intervention
Related Studies:
Other Fibromyalgia Clinical Trials
Other Massachusetts Clinical Trials
Other Belmont Clinical Trials
Gabapentin in Fibromyalgia Trial (GIFT)
|
|
|
|
|
|
|
|
